Principles of dopaminergic therapy for Parkinson’s disease


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

In the treatment of Parkinson’s disease (PD), the correction of dopamine deficiency with dopaminergic drugs, which can have both short-term and long-term effects, is of key importance. Longstanding maintenance of a long-term effect is one of the most important areas in modern approaches to optimizing the treatment of PD, one of which is the use of long-acting dopaminergic receptor agonists. The early transition to a combination therapy of PD provides a more optimal anti-Parkinsonian effect in patients with early and advanced stages, allowing maximum use of mobility resources in PD patients. High adherence to therapy and flexible dose titration make long-acting ropinirole one of the most effective treatments for PD. The article presents data on the possibility of using ropinirole in the practice of treating PD.

Texto integral

Acesso é fechado

Sobre autores

Oleg Levin

Russian Medical Academy of Continuous Professional Education

Email: neurolev@mail.iu
Department of Neurology

A. Chimagomedova

Center for Extrapyramidal Diseases

MD, Professor, Head of the Department of Neurology

Bibliografia

  1. Голубев В.Л., Левин Я.И., Вейн А.М. Болезнь Паркинсона и синдром паркинсонизма. М., 1999.
  2. Левин О.С., Федорова Н.В., Смоленцева И.Г. Агонисты дофаминовых рецепторов в лечении болезни Паркинсона. РМЖ. 2000;15-6:643-
  3. Левин О.С., Смоленцева И.Г., Цередсодном Б. и др. Влияние дофаминергической терапии на нейропсихологические функции у больных болезнью Паркинсона. Неврологический журнал. 2004;3:31-7.
  4. Левин О.С., Федорова Н.В. Болезнь Паркинсона. М., 2016.
  5. Левин О.С., Смоленцева И.Г., Цэрэнсодном Б. Эффективность прамипексола при болезни Паркинсона (по данным открытого 12-месячного исследования). Фарматека. 2007;1:28-34.
  6. Протокол ведения больных. Болезнь Паркинсона. Проблемы стандартизации в здравоохранении. 2005;3:74-166.
  7. Яхно Н.Н., Нодель М.Р., Федорова Н.В. и др. Эффективность и переносимость прамипексола при продолжительной терапии у пациентов с болезнью Паркинсона. Неврологический журнал. 2004;3:25-30.
  8. Antonini A., Tolosa E., Mizuno Y., et al. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet. Neurol. 2009; 8:929-37.
  9. Chaudhuri K.R., Martinez-Martin P., Rolfe K.A., et al. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease. Eur. J. Neurol. 2011. doi: 10.1111/j.1468-1331.
  10. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther 2001;23: 1296-310.
  11. Grosset K., Needleman F., Macphee G., Grosset D. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five-drug dose conversion table. Mov. Disord. 2004;19(11):1370-74.
  12. Grosset K.A., Reid J.L., Grosset D.G. Medicine-taking behavior: Implications of suboptimal compliance in Parkinson's disease. Movement Disorders. 2008;20:1397-404.
  13. Hauser R.A., Rascol O., Korczyn A.D., et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov. Disord. 2007;22:2409-17.
  14. Leopold N.A., Polansky M., Hurka M.R. Drug adherence in Parkinson's disease. Mov. Disord. 2004;19(5):513-17.
  15. Lyons K.E., Fahwa R. An Open-Label Conversion Study of Pramipexole to Ropinirole Prolonged Release in Parkinson's Disease. Mov Disord. 2009;24: 2121-27.
  16. Nutt J.G., Carter J.H., Woodward W.R. Long-duration response to levodopa. Neurology. 1995;45: 1613-16.
  17. Nutt J.G., Carter J.H., Van Houten L., et al. Short-and long-duration responses to levodopa during the first year of levodopa therapy. Ann. Neurol. 1997;42:349-55.
  18. Pahwa R., Stacy M.A., Factor S.A. Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68:1108-15.
  19. Poceta J.S., Parsons L., Engelland S. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. Sleep Med. 2009;10:129-33.
  20. Rascol O., Brooks D.J., Korczyn A.D., et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. New Eng. J. Med. 2000;342:1484-91.
  21. Rascol O., Brooks D.J., Korczyn A.D., et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov. 2006;21:1844-50.
  22. Sethi K.D., O'Brien C.F., Hammerstad J.P., et al. Ropinirole for the treatment of early Parkinson disease: A 12-month experience. Arch. Neurol. 1998;55:1211-16.
  23. Schapira A.H., Olanow C.W. Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann. Neurol. 2008;64(Suppl. 2):47-55.
  24. Stocchi F., Hersh B.P., Scott B.L., et al. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: A randomized, double-blind, non-inferiority crossover study. Curr. Med. Res. Opin. 2008;24:2883-95.
  25. Stocchi F., Giorgi L., Hunter B., et al. PREPARED: Comparison of Prolonged and Immediate Release Ropinirole in Advanced Parkinson's Disease. Mov. Disord. 2011. doi: 10.1002/mds.23498.
  26. Stowe R., Ives N., Clarke C.E., et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications. Coch. Datab. Syst. Rev. 2010;7:CD007166. doi: 10.1002/14651858. CD007166. pub2.
  27. Thobois S. Proposed dose equivalence for rapid switch between dopamine agonists in Parkinson disease. Clin.Ther. 2006;28:1-12.
  28. Tomlinson C.L., Stowe R., Patel S., et al. Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease. Mov. Disord. 2010;25: 2649-85.
  29. Tompson D., Vearer D. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: Results of two randomized studies in patients with Parkinson's disease. Clin. Ther. 2007;29:2654-66.
  30. Watts R.L., Lyons K.E., Pahwa R., et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov. Disord. 2010;25:858-66.
  31. Weintraub D., Koester J., Potenza M.N., et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 2010;67:589.
  32. Whone A.L., Watts R.L., Stoessl A.J., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann. Neurol. 2003;54:93-101.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies